All In Biotech

Drug Trial Radar · NCT01591902

Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes

Last checked: Nov 20, 2026Latest source record: Sep 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 129 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

129

Actual

Start

Jun 2012

Primary completion

May 2018

Study completion Aug 2018

Sponsor

Lead sponsor
TheratechnologiesIndustry
Sponsor type
Industry
First posted
May 4, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To show the non-inferiority of EGRIFTA® vs. placebo in the development or progression of Diabetic Retinopathy in HIV-infected subjects with concomitant abdominal lipohypertrophy and Type 2 diabetes mellitus (T2DM).

Conditions

  • Diabetic Retinopathy
  • HIV

Interventions

  • TesamorelinDrug

    Daily 2 mg subcutaneous injections of tesamorelin

  • Placebo-ControlDrug

    3.0 mL vials

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in percentages of subjects with a 3-step or greater progression (from both eyes) on the Early Treatment Diabetic Retinopathy Study (ETDRS) PERSON scale.Time frame: 3 years

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Southwest Center for HIV/AIDS

    Phoenix, Arizona

  • Spectrum Medical Group

    Phoenix, Arizona

  • 5P21 Rand Schrader Clinic

    Los Angeles, California

  • University of California CARE Clinic, Los Angeles

    Los Angeles, California

  • Palmtree Clinical Research, Inc.

    Palm Springs, California

  • UCSD Antiviral Research Center

    San Diego, California

  • VAMC, Infectious Disease Section 111W

    San Francisco, California

  • Capital Medical Associates, PC

    Washington D.C., District of Columbia

  • Gary J. Richmond, M.D., PA

    Fort Lauderdale, Florida

  • Orange County Health Department

    Orlando, Florida

  • Triple O Research Institute

    West Palm Beach, Florida

  • Rowan Tree Medical , P.A.

    Wilton Manors, Florida

  • Be Well Medical Center, P.C.

    Berkley, Michigan

  • Southampton Clinical Research, Inc d.b.a. Central West Clinical Research

    St Louis, Missouri

  • Southampton Healthcare, Inc.

    St Louis, Missouri

  • South Jersey Infectious Disease

    Somers Point, New Jersey

  • Harold Hamm Diabetes Center at the University of Oklahoma

    Oklahoma City, Oklahoma

  • Fanno Creek Clinic, LLC

    Portland, Oregon

  • Central Texas Clinical Research

    Austin, Texas

  • St. Hope Foundation, Inc.

    Bellaire, Texas

  • Dallas VA Medical Center

    Dallas, Texas

  • UT Southwestern Medical Center, Atten: HIV Research Unit

    Dallas, Texas

  • Research Access Network

    Houston, Texas

  • Virginia Mason Medical Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.